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A B S T R A C T
Studies demonstrate that damage to gut microbiota is associated with some brain disorders including neuro-
degenerative diseases such as Alzheimer's disease (AD). Accordingly, supporting gut microbiota has been con-
sidered as a possible strategy for AD treatment. We evaluated behavioral and electrophysiological aspects of the
brain function in an animal model of AD made by intracerebroventricular injection of β-amyloid. Two groups of
control rats recieved either water as vehicle (Con) or probitics (Pro+Con). Also two groups of Alzheimeric
animals were treated by either vehicle (Alz) or probiotics (Pro+Alz). Sham group was only subjected to surgical
procedure and received the vehicle. Spatial learning and memory was assessed in Morris water maze. Also, basic
synaptic transmission and long-term potentiation (LTP) were assessed by recording ﬁeld excitatory postsynaptic
potentials (fEPSPs) in hippocampus. Change in anti-oxidant/oxidant factors was assessed via measuring plasma
level of total anti-oxidant capacity (TAC) and malondealdehyde (MDA). Brain staining was done to conﬁrm β-
amyloid accumulation. Fecal bacteria quantiﬁcation was accomplished to ﬁnd how probiotic supplement af-
fected gut microbiota. We found that while the Alz animals displayed a weak spatial performance, probiotic
treatment improved the maze navigation in the Pro+Alz rats. Whereas basic synaptic transmission remained
unchanged in the Alz rats, LTP was suppressed in this group. Probiotic treatment signiﬁcantly restored LTP in the
Pro+Alz group and further enhanced it in the Pro+Con rats. The intervention also showed a favorable eﬀect
on balance of the anti-oxidant/oxidant biomarkers in the Pro+Alz rats. This study provides the ﬁrst proof on
positive eﬀect of probiotics on synaptic plasticity in an animal model of AD.
1. Introduction
Alzheimer’s disease (AD), the most prevalent of all dementias, af-
fects an estimated 47 million people worldwide [1]. It is etiologically
resulted from a precipitation of extracellular β-amyloid plaques, for-
mation of neuroﬁbrillary tangles, neuroinﬂammation, neuronal injury
and damage to neuronal synapses [2]. AD results in a severe and pro-
gressive memory impairment, deterioration of cognitive abilities and
behavioral alterations [2].
Gut microbiota-brain-axis describes a bidirectional communication
between brain and gut by which brain modulates the gastrointestinal
tract and, gut aﬀects the brain function and behavior. Composition of
the gut microbiota varies between healthy and diseased individuals for
many diseases so that the intestinal microﬂora promises new potentials
for prevention and/or treatment of diseases.
Probiotics as the helpful microorganisms are beneﬁcial to humans
and animals when adequately administered. Probiotic bacteria make
proﬁcient interaction with the gut microbiota and provide health ben-
eﬁts [3].
In recent years, attempts are devoted to ﬁnd a link between the gut
microbiome with the cognitive function [4] as well as the neurological
disease related cognitive dysfunction like AD [5]. Accordingly, evi-
dence indicates that a normal function of brain strongly depends on
natural composition of the gut ﬂora, known as eubiosis, and that any
dysbiosis, reﬂected in decrease of intestinal biodiversity or increase of
pathogenic bacteria, leads to some damages to brain functions.
A growing body of researches has been dedicated to uncover if
supporting the gut microbiota by probiotic bacteria inﬂuences the brain
dysfunctions. Indeed, probiotics are found to aﬀect neurological dis-
orders by increasing diversity and compositions of the gut microbiome
[6].
The hippocampus, having interconnections with cortical association
https://doi.org/10.1016/j.bbr.2019.112183
Received 8 May 2019; Received in revised form 19 August 2019; Accepted 27 August 2019
⁎ Corresponding authors.
E-mail addresses: gsepehri@yahoo.com (G. Sepehri), salami-m@kaums.ac.ir (M. Salami).
Behavioural Brain Research 376 (2019) 112183
Available online 28 August 2019
0166-4328/ © 2019 Elsevier B.V. All rights reserved.
T
areas, plays a pivotal role in many processes including consolidation of
recent memory [7]. Hippocampal neuronal circuits have typically been
subjected to assessment of normal synaptic transmission as well as long-
term potentiation (LTP) and long-term depression (LTD), known as
candidate mechanisms by which long lasting memories are con-
solidated. Particularly, LTP as an experimental form of synaptic plas-
ticity, is greatly investigated in the CA3-CA1 pathway of hippocampus.
The hippocampus is susceptible to neural damages caused by AD. De-
generative symptoms including deﬁcits in performance of the hippo-
campus dependent cognitive abilities such as spatial learning and
memory, are reported in AD [8]. Declined LTP is also reported in an-
imal models of AD [9].
Growing evidence from experimental and clinical studies designate
positive eﬀects of probiotics on the cognitive phenomena in normal
animals [10] and humans [11], and animal models of AD [12,13]. We
reported the ﬁrst clinical trial demonstrating the favorable eﬀect of
probiotic administration on the cognitive indices of the people with AD
[14]. However, despite the convinced signs connecting the probiotic
bacteria with neurotransmitters and neuromodulators, data showing
the eﬀect of probiotics on activity of neuronal circuits is almost missing.
The only reports are provided by Distrutti et al. [15] and Davari et al.
[16], both demonstrating the facilitatory eﬀect of probiotic supple-
ments on synaptic transmission. To date, no report exists on the eﬀect of
probiotics on synaptic activity in animal models of AD. In the present
study, using β-amyloid administered animals, we evaluated the eﬀect of
a mixture of probiotic bacteria on the behavioral and electro-
physiological aspects of cognitive functions in an animal model of AD.
2. Materials and methods
Adult normal reared male Wistar rats weighing 200–250 g were
chosen for experimentation. They were provided by the Experimental
Animal Breeding Center of Kashan University of Medical Sciences. The
rats were housed in a temperature (24 ± 2 °C) and humidity-controlled
(60%) condition with a standard 12 h-12 h light/dark cycle and free
access to food and water ad libitum. The animals were housed in a
speciﬁc room during experiments, except when performing the beha-
vioral test. All experimental procedures were conducted in accordance
with guidelines of the Ethical Committee of Kashan University of
Medical Sciences.
2.1. Treatment groups
Rats were arbitrarily distributed into 5 groups. Control (Con) group
received drinking water (as vehicle). Two groups of the animals were
subjected to surgery procedure for intracerebroventricular (ICV) in-
jection of β-amyloid peptide (see below). Of them, one group (Alz) was
treated by the vehicle and another group (Pro+Alz) was treated by the
probiotics after the β-amyloid injection. Sham group was also subjected
to the surgery procedure and received the vehicle. A normal group of
rats also received probiotics (Pro+Con). The treatments lasted for 56
days (Fig. 1).
2.2. Preparation and administration of the probiotics
The probiotic supplement was a mixture of bacteria composed of
Lactobacillus acidophilus, Biﬁdobacterium biﬁdum and Biﬁdobacterium
longum in capsulated form (provided by Gostaresh Milad Pharmed
Company-Tehran, I.R. Iran). Each capsule was consisting 500mg of the
bacteria mixture with a total CFU of 15×109. The probiotics were
dissolved in drinking water and administered via intragastric gavage.
2.3. Animal model of Alzheimer's disease
Crystallized form of β-amyloid 1–42 (purchased from Sigma-Aldrich
Company) was used for creating animal model of AD. β-amyloid was
dissolved in distilled water to a concentration of 1mg/1mL and ag-
gregated by incubation at 37 °C for 1 week before ICV injections.
Animals were anesthetized with intraperitoneal co-injection of keta-
mine (70mg/kg) and xylazine (10mg/kg) and placed in stereotaxic
frame. Characteristics of the injection site was: anteroposterior = -
0.8 mm, mediolateral =±1.6mm, dorsoventral =3.5mm. A small
hole was drilled on the skull and, via a Hamilton syringe, a single dose
including 10 μl (containing 10 μg) of aggregated β-amyloid was injected
into the lateral ventricles of the brain. Two injections (containing a
total of 20 μg β-amyloid) were administered during two consecutive
days.
2.4. Behavioral experiments
2.4.1. The maze apparatus
The Morris water maze was used to investigate spatial learning and
memory ability. The procedure was carried out according to the pre-
vious protocol with minor modiﬁcations [17]. The maze was comprised
of a galvanized circular water tank (diameter, 140 cm; height, 60 cm)
equipped with a platform (diameter, 10 cm) submerged 1.5 −2 cm
below the surface of the water and placed in center of a quadrant. It was
ﬁlled with water to a depth of 30 cm heated to room temperature
(24 ± 2 °C). The pool was located in a dark room with a number of
extra-maze visual cues placed on the walls around the tank. Tracking of
animal movement was attained with video-tracking system (RADIAB-7,
I. R. Iran). It comprises a video camera attached to a computer placed
above the center of the tank to record and analyze the trajectory of the
rats.
2.4.2. Spatial performances
The animals underwent two phases of maze performance including
the acquisition and probe trial phases.
2.4.2.1. Acquisition phase. The acquisition phase consisted of 4
consecutive days, in which the animals were introduced to the maze
four trials/day with a 15min inter-trial interval. The animals had to
search for the stationary platform from one of four diﬀerent start points,
designated as North, South, East, and West. Starting points were
determined randomly by a software and each was used once per
session. The animals were placed successively in all four quadrants of
the tank facing the wall of the tank. If rats were unable to ﬁnd the
platform within 60 s, they were guided to the platform and remained
placed there for 10 s. The time it took the rat to ﬁnd the platform was
considered as index of learning ability.
2.4.2.2. Probe trial test. The day following completion of the
acquisition trials, the probe trial test was performed to assess memory
consolidation. This trial was directed by eliminating the platform from
the tank. The rats were released in the opposite quadrant of the
platform facing the pool wall and allowed to navigate the maze for
30 s. The retention of the spatial memory was evaluated by analyzing
the time spent in the same location of the original platform.
2.5. Electrophysiological experiments
Field excitatory postsynaptic potentials (fEPSPs) in the hippo-
campus were recorded based on our previously protocol [18].
2.5.1. Surgery and electrode implantation
The rats were anesthetized with intraperitoneal injection of ur-
ethane (1.5 g/kg) and ﬁxed in a stereotaxic instrument (Borj Sanat, I.R.
Iran). After exposing the surface of the skull, a dental drill was used to
create two holes above the brain, and then, incised the dura matter. One
hole was drilled for the recording electrode (1mm diameter, 4.2 mm
posterior to bregma, 3.8 mm lateral to the midline) and another one, for
the stimulating electrode (1mm diameter, 3.4 mm posterior to bregma,
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2.5 mm lateral to the midline). All coordinates were based on the ste-
reotaxic atlas. Electrodes were made from Teﬂon-coated stainless steel
wire (0.008 inch outside diameter) exposed only at the tip (tip se-
paration was almost 0.10mm). The recording and stimulating elec-
trodes were lowered into the CA1 stratum radiatum and the Schaﬀer
collaterals of the hippocampus, respectively. Extracellular recordings
were referenced to an indiﬀerent site on the skull.
2.5.2. Recording protocols
2.5.2.1. Paired pulse facilitation. Before the baseline recording, the
responses in the CA3-CA1 pathway were subjected to paired pulse
facilitation to evaluate if the performing protocol is correctly recording
the NMDA receptor dependent responses. Two stimuli with a 50ms
inter-stimulus interval were applied to the path. Considering the
amplitude of fEPSPs, the recording protocol was continued if the
second response was facilitated compared to the ﬁrst one.
2.5.2.2. Baseline responses. Input-output curves were generated by
increasing stimulus intensity in 5–10 μA increments and recording
fEPSPs amplitudes. Accordingly, stimulus intensity was regulated to
evoke a fEPSP with about 60% of the maximal response. Constant
current stimulation (two sweeps/min at 30 s intervals) was
programmed by a computer software (Neurotrace, I.R. Iran) and
delivered to a stimulator/isolator unit (WPI-A365). The test pulses
were applied to the Schaﬀer collaterals and fEPSPs of the CA1 area were
attained. When the responses were stabilized, stable baseline fEPSPs (as
pre-tetanus responses) were recorded for 30min.
2.5.2.3. Induction of LTP. LTP was induced by high-frequency
stimulation (HFS) of 100 Hz (10 bursts of 10 stimuli, 0.1 ms stimulus
duration, and 2 s inter-burst intervals). Then, the post-HFS fEPSPs were
recorded for 90min. The fEPSPs were ampliﬁed on a preampliﬁer
(Electromadule, WSI, I.R. Iran), ﬁltered at 1–3000 Hz, digitized (10
points/ms) and stored for oﬄine analysis. The size of the amplitude was
measured from the baseline to the lowest point of the fEPSP. The data
were analyzed for the changes in amplitude of the pre- and post-tetanus
fEPSPs and normalized by taking the pre-tetanus amplitude of fEPSPs as
100% and comparing the post-tetanus fEPSPs with it. For illustrations,
the data were compressed to 2-minute averages.
2.6. Fecal bacteria quantiﬁcation
Duplicated MRS-agar was used to quantify the number of all variety
of anaerobic bacteria in feces. Brieﬂy, fecal samples were collected from
the rats in the end of the probiotic treatment. The fecal samples were
10-fold serially diluted in saline. One gram of feces was added to a
strilled tube ﬁlled with 9ml normal saline and homogenized by mixing
with a vortex. Then, the dilutions were placed on duplicated agar plate
to determine the number of colonies in that dilution. All plates were
incubated at 37 °C for 72 h. Total fecal bacteria were quantiﬁed by
counting colony forming units (CFU) on MRS plates corresponding to
the last readable dilution. The quantiﬁcation was occurred 56 days after
either probiotic or vehicle treatment. The results were expressed as
CFU/g stool, based on the dilution used for plating.
2.7. Measurement of the biomarkers
Blood samples were pooled from right atrium of all animals after the
electrophysiological experiments were accomplished. The samples were
centrifuged at 2500 rpm for 5min and attained plasma was kept frozen
at -80 °C until measurements. Serum total antioxidant capacity (TAC)
was quantiﬁed using the method of ferric reducing antioxidant power
method developed by Benzie and Strain. Plasma concentration of
malondialdehyde (MDA) was measured by the thiobarbituric acid re-
active substance method.
2.8. Tissue preparation and histological examinations
The brain of anesthetized animals was perfused with saline followed
by 10% formalin (PH=7.4). The brains were quickly removed from the
skull and stored in 4 °C until use. For brain sectioning, the brains were
embedded in paraﬃn and then cut on a sliding microtome into sections
with a thickness of about 8 μm. The brain sections were mounted on
slides and dried by leaving the slide at room temperature overnight. We
used the Bielschowsky silver staining for the histological diagnosis of β-
amyloid plaques. Brieﬂy, the sections were deparaﬃnized and rehy-
drated and incubated in pre-warmed (37 °C) 20% AgNO3 solution for
25min. Then, the sections were washed with dH2O and incubated for
another 15min with the same solution. The sections were incubated for
several minutes until they darken in the AgNO3/ammonium solution
with developer (20ml of formalin, a drop of concentrated HNO3, 0.5 g
of citric acid, and 100ml of dH2O). Then, the sections were washed and
ﬁxated in 5% sodium thiosulfate for 5min. Finally, the sections were
washed, dehydrated, hyalinized and mounted [19].
2.9. Statistics
Data were analyzed using SPSS 18.0 software for windows. All va-
lues were expressed as means ± SEM. Two-way ANOVA was used to
test the signiﬁcance of diﬀerence among diﬀerent groups followed by
LSD post hoc. Nonparametric tests were applied to the data taken from
quantiﬁcation of fecal bacteria. Diﬀerences with a P value of< 0.05
Fig. 1. Summary of experiment ﬂow.
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were considered statistically signiﬁcant.
3. Results
3.1. Spatial learning and memory
To evaluate spatial aspects of learning and memory the animals
were introduced to navigation in Morris water maze. The task learning
and the memory consolidation were assessed through the acquisition
and probe trial phases, respectively.
3.1.1. Acquisition phase
Four days training of the animals in the water maze indicated a
considerable variation between the testing groups (F4, 179= 9.52;
P < 0.000). The vehicle treated Sham rats showed no diﬀerence in the
maze performance when compared to their Con counterparts. The β-
amyloid administered Alz group demonstrated a pronounced lower
function in the maze steering in comparison to either Con or Sham
groups (P < 0.001), where the Alz animals needed almost 50% more
time to locate the platform. Treating the animals with the probiotic
mixture improved the maze navigation so that the Pro+Alz rats found
the platform during a shorter time than did their Alz counterparts
(P < 0.004). Also the Pro+Con rats showed a higher maze perfor-
mance compared to the Con (P < 0.014) and Sham (P < 0.009) ani-
mals (Fig. 2A).
3.1.2. Probe trial phase
According to the probe trial test the rats in all groups analogously
searched the maze. Statistical analysis showed that no signiﬁcant dif-
ference (F4, 40= 0.58; P < 0.67) was evident between the testing
groups (Fig. 2B).
3.2. Electrophysiological recordings
3.2.1. Baseline fEPSPs
The baseline synaptic fEPSPs were recorded in the CA1 area in re-
sponse to stimulation of the Schaﬀer collaterals. Analysis of variance
showed no diﬀerence (F4, 295= 1.5; P < 0.21) between amplitude of
the baseline fEPSPs in diﬀerent testing groups (Fig. 3A).
3.2.2. Induction of LTP
Application of the HFS on the Schaﬀer collaterals resulted in a
substantial LTP (45%) in the hippocampal CA1 area of the Con animals
(6 out of 7 animals). Although the augmentation decreased over time,
however, the circuit remained potentiated as long as the recording
lasted showing a signiﬁcant diﬀerence between the pre- and post-HFS
fEPSPs (P < 0.001). The tetanic stimulation elicited an almost similar
enhancement (49%) in the Sham group where the amplitude size of
post-HFS fEPSPs was enhanced in 7 out of 8 rats (P < 0.001). Injection
of β-amyloid markedly diminished the level of potentiation (27%) and
the number of animals demonstrating LTP (3 out of 6 animals) in the
Alz rats which was statistically signiﬁcant in comparison to the Con
animals (P < 0.001). We observed the least post tetanic potentiation in
the Alz group that was steadily kept over the experiments. The probiotic
supplementation successfully restored the synaptic plasticity in the β-
amyloid injected rats so that a considerable LTP (40%, in 5 out of 7 rats)
was induced in the CA1 area of hippocampus in the Pro+Alz rats
(P < 0.001 versus the Alz group). Interestingly, the HFS induced a
robust LTP (74%) in all 7 rats in the Pro+Con group (P < 0.001)
indicating the highest potentiation in our study. Fig. 3B and C, illus-
trates the pre- and post-tetanus traces and amplitude change of fEPSPs,
respectively.
Fig. 2. The eﬀect of probiotic supplementation on the spatial
memory performance of the testing groups. A) Curves re-
present the function of animals in diﬀerent groups during
four days of the acquisition phase. β-amyloid injection
markedly weakened the task learning in the Alz (n= 8) an-
imals compared to the Con (n= 10) and Sham (n=10)
groups. Treatment with the probiotic mixture improved the
maze searching in the Pro+Alz rats (n=8; P < 0.004
versus the Alz group) and also in the Pro+Con rats (n= 9)
compared to the Con (P < 0.014) and Sham (P < 0.009)
groups. B) Histograms indicate no diﬀerence between the
diﬀerent groups in consolidating the learned target during
the probe test trial.
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Fig. 3. A) Mean amplitude of the baseline fEPSPs recorded from the
CA1 area of hippocampus. Both β-amyloid injection and probiotic
treatment had no signiﬁcant eﬀect on the baseline recordings. B)
Representative fEPSPs in the CA1 area evoked by the Schaﬀer col-
lateral ﬁbers stimulation in the hippocampus. Records were ob-
tained before (baseline) and 30, 60 and 90min after the HFS. Each
trace represents an average of ten consecutive records. C) Magnitude
of change in the amplitude of hippocampal recordings after tetani-
zation of the CA3–CA1 pathway. Whereas the tetanic stimulation
induced a substantial LTP (P < 0.001) in the Con rats (n= 7) it
elicited the lowest potentiation in the Alz (n= 6) animals. The
probiotic supplement signiﬁcantly enhanced the magnitude of po-
tentiation in the Pro+Alz (n=7) group compared to the Alz ani-
mals (P < 0.001). The probiotic treatment led to a stronger synaptic
plasticity in the Pro+Con (n= 7) compared to both Con (n= 7)
and Sham (n=8) groups (P < 0.001).
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3.3. Histological veriﬁcation for β-amyloid accumulation
To prove whether or not the β-amyloid administration led to ac-
cumulation of the peptide in the neural tissue, sections of the brains
were exposed to the Bielschowsky silver staining method. Microscopic
assessments conﬁrmed precipitation the β-amyloid peptide in the brain
of rats in the Alz group. The β-amyloid plaques were observed in nei-
ther Con nor Pro+Alz animals indicating that 8-week probiotic
treatment successfully prevented accumulation of the peptide. Fig. 4
illustrates β-amyloid plaques in micrographs prepared from brain of the
Alz rats.
3.4. The eﬀect of probiotic treatment on plasma level of anti-oxidant/
oxidant biomarkers
To assess how the anti-oxidant/oxidant factors are sensitive to the
probiotic treatment, the plasma level of TAC, as an anti-oxidant index,
and MDA as an oxidant index, were measured.
Our results indicated that injection of β-amyloid in the animal
model of AD highly increased MDA concentration. The values are dif-
ferent between the Alz group with the Con and Sham groups
(P < 0.001). The probiotic intervention eﬃciently decreased the oxi-
dant factor MDA in the Pro+Alz animals (P < 0.001), when com-
pared to the Alz rats. However, the MDA level was still higher in the
Pro+Alz group compared to the Con and Sham groups (Fig. 5A).
On the other hand, the β-amyloid injection signiﬁcantly decreased
the TAC level of plasma in the Alz group (P < 0.001 versus the Con
and Sham groups). The probiotic supplementation substantially ele-
vated the plasma concentration of TAC in the Pro+Alz animals so that
a signiﬁcant diﬀerence (P < 0.01) was evident between this group and
the Alz group (Fig. 5B).
3.5. Conﬁrmation of gut microbiota supporting by the probiotic supplement
Counting colony forming units were carried out to make an esti-
mation of fecal bacteria. Total count of bacteria was quantiﬁed 8 weeks
after the treatments. Our ﬁndings veriﬁed that the probiotic treatment
markedly increased (by a power of about 100) in the fecal count of
Fig. 4. Micrographs of the brain sections prepared by Bielschowsky silver method in the A) Con, B) Alz and C) Pro+Alz groups. Arrow indicates the deposition of
amyloidal plaques in brain of the β-amyloid injected Alz Animals. β-amyloid plaques were not visible in the brain of either Con or Pro+Alz rats.
Fig. 5. The eﬀect of probiotic treatment on plasma level of
anti-oxidant/oxidant biomarkers.
A) While the MDA concentration of plasma was increased in
the Alz group, it was decreased in the probiotic treated groups.
***P < 0.001, Alz versus Sham and Con groups.
&&& P < 0.0001, Pro+Alz versus Con group.
*P < 0.01, Con and Pro+Con groups versus Sham group.
###P< 0.002, Pro+Alz versus Alz group.
B) The eﬀect of probiotic treatment on plasma level of TAC. β-
amyloid injection reduced the total anti-oxidant capacity of
plasma in the Alz group. The TAC level was increased in the
probiotic treated Pro+Alz rats.
***P < 0.01, Alz versus Sham and Con groups.
& P < 0.0001, Pro+Alz versus Con group.
### P < 0.003, Pro+Alz versus Alz group.
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bacteria. The increments are visible when the vehicle treated Con and
Alz groups are compared with their probiotic treated counterparts, the
Pro+Con (P < 0.0087) and Pro+Alz (P < 0.0079) groups, respec-
tively. This data verify that the probiotic supplementation aﬀected the
gut microbiome. Table 1 represents the values indicating inﬂuence of
the probiotic treatment on the count of gut ﬂora.
4. Discussion
Results of the present study showed that the probiotic supple-
mentation considerably improved the hippocampus dependent spatial
memory and synaptic plasticity in the β-amyloid administered rats. The
intervention also favorably inﬂuenced the balance of the anti-oxidant/
oxidant factors.
4.1. The eﬀect of probiotics on behavioral performances
Our ﬁndings showed that the β-amyloid administration con-
siderably disturb cognitive performances which is reﬂected in the im-
paired spatial navigation in water maze. The probiotic treatment highly
improved the spatial performance in the Pro+Alz group and further
enhanced the maze navigation in the Pro+Con animals.
Some preclinical and clinical studies have attempted to elucidate
how probiotic bacteria improve deﬁcits in learning and memory. On
one hand, evidence shows that dysbiosis due to damage to gut micro-
biota in animal models modulates cognitive behaviors including
learning and memory [20]. On the other hand, experimental and clin-
ical studies using probiotic supplements indicate improvement of the
brain cognitive function. Studies of Bercik et al. [21] and Savignac et al.
[22] demonstrated that Biﬁdobacterium longum improved learning and
memory. Also, a clinical study showed that Biﬁdobacterium longum 1714
consumption improved cognitive performance and enhanced visuos-
patial memory [23]. Additional evidences come+ from the positive
eﬀect of probiotics on learning and memory capabilities in aged animal
[10] and human subjects [11]. Helpful eﬀect of probiotics on learning
and memory is also shown in some other experimental models such as
diabetic [16] and anxiety animal models [24] with impaired spatial
memory.
In a study on a model of AD, rats were orally received strains of
lactobaccili and biﬁdobacteria. The intervention decreased β-amyloid
plaque size and improved spatial memory. In addition, MDA and su-
peroxide dismutase (SOD) reached optimal levels in hippocampus,
contributing to the clearance of plaques [25]. Bonﬁli et al. also found
that probiotic supplements improved cognitive function in a β-amyloid
treated animal model of AD [12]. In another animal model of AD,
Nimgampalle and Kuna reported that treating with Lactobacillus plan-
tarum displayed anti-Alzheimer properties against D-Galactose induced
AD [13]. Using diﬀerent strains of Lactobacilli and Biﬁdobacteria
Kiousi et al. found that probiotics may delay onset of AD and minimize
its manifestations. The intervention normalized levels of MDA and SOD
in hippocampus, leading to clearance of β-amyloid plaque, and im-
proved spatial memory [26].
In the ﬁrst published clinical trial on AD patients, we treated the
patients with a probiotic mixture (Lactobacillus acidophilus, Lactobacillus
casei, Biﬁdobacterium biﬁdum, and Lactobacillus fermentum) and in-
troduced them to mini-mental state examination (MMSE) cognitive test.
The probiotic treated subjects gained more score than the controls.
Also, the intervention counteracted some oxidative stressors and
improved some metabolic statuses [14]. However, in another clinical
trial performed on signiﬁcantly older AD patients with lower baseline
cognitive scores, we found that the probiotic supplementation was in-
eﬀective [27], indicating that the eﬃcacy of probiotics on cognition
depends on, at least, age and/or severity of the cognitive disorder.
What are the probable action mechanisms by which the probiotic
bacteria favorably aﬀect the impaired cognition in AD patients or AD
animal models? Evidence suggests wide range of action mechanisms
including neuronal, immune, endocrine and metabolic pathways.
However, scarce researches have considered the eﬀect of probiotics on
AD induced impaired cognition.
Some evidence designates the reason of disrupting eﬀect of β-
amyloid plaques on the cognition and synaptic transmission. Choi et al.
demonstrated that fermentation with probiotics increased cognitive
activity by stimulating secretion of memory-related neurotransmitters
such as acetylcholine and glutamate and, inhibiting acetylcholine es-
terase activity in brain [28].
Gut microbiota is important for stability of intestinal permeability.
Damage to gut microbiota leads to increased intestinal permeability,
that, in turn, increases incidence of neurodegeneration disorders [29].
In this sense, it can be suggested that AD may begin in gut. On the other
hand, probiotics are found to improve the function of intestinal epi-
thelial and, thus, decrease permeability [30]; possible accounting for
the beneﬁcial eﬀects of probiotics on cognitive function.
Short-chain fatty acids (SCFAs) are known as the major metabolites
produced by the microbiome. It is proved that elevated amount of
SCFAs such as butyrate by prebiotics and probiotics provoke an increase
in BDNF and a decrease in pro-inﬂammatory cytokines concentration in
the hippocampus leading to improved learning and memory [31].
4.2. The eﬀect of probiotics on synaptic transmission
In parallel to the behavioral ﬁndings, our electrophysiological ex-
periments resulted in a suppressed hippocampal LTP in the Alz animals.
The probiotic administration substantially restored synaptic plasticity
in the tetanized fEPSPs. Furthermore, it enhanced the hippocampal LTP
in the normal reared rats.
Very few studies have addressed the direct regulating eﬀect of the
gut ﬂora and probiotics on activity level of neuronal circuits. It is found
that the gut microbiota aﬀects myelination [32] and neurogenesis [33].
Using germ-free animals, McVey Neufeld et al. proved that commensal
intestinal microbiota are necessary for normal excitability of gut sen-
sory neurons and this provide a potential mechanism for transfer of
information between microbiota and nervous system [34]. Through
aﬀecting levels of neuromodolators or neurotransmitters, probiotics can
inﬂuence brain neurochemistry. The regulating eﬀect of probiotic
bacteria on BDNF, GABA, serotonin, dopamine, norepinephrine and
acetylcholine has been already shown. In our previous work we de-
monstrated that the probiotic treatment successfully restored dimin-
ished hippocampal LTP in an animal model of diabetes mellitus [16].
NMDA receptors are involved in excitatory synaptic transmission in
neural circuits of the hippocampus. LTP in the CA3-CA1 pathway of the
hippocampus is NMDA receptor dependent. NMDA receptor channels
are heteromeric tetramers of GLUR1 and GLUR2A-D subunits. Evidence
speciﬁes direct interaction of β-amyloid with postsynaptic NMDA re-
ceptors [35]. Indeed, in animal models of AD, β-amyloid accumulation
can cause abnormal activation of NMDA receptors [36]. Based on,
Parsons et al. found that disturbed synaptic transmission in AD can be
selectively decreased by GluN2B selective antagonists like memantine
[37]. Romo-Araiza et al demonstrated that treating animals with a
mixture of the probiotic bacteria Enterococcus faecium and inulin in-
creases NMDA/AMPA ratio resulting in a robust LTP [31].
Additionally, it is shown that β-amyloid has a harmful eﬀect on
function of BDNF, having regulatory actions on the brain including
synaptic plasticity [38], and that inhibition of NMDA receptors by
memantine prevents the loss of BDNF function induced by β-amyloid
Table 1
Viable counts (CFU/gr) of bacteria in feces of the diﬀerent testing groups after 8
weeks treatment with either vehicle or probiotics.
Group Con Pro+Con Sham Alz Pro+Alz
CFU/gr 256×108 1010≤ 156×108 60×108 27×1010
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[39]. Thus, concerning deteriorated synaptic plasticity in the Alz ani-
mals, a possibility could be, through deleterious eﬀect on the NMDA
receptors as well as BDNF function, β-amyloid attenuates both normal
as well as tetanized synaptic activity. Distrutti et al. found that a
composition of probiotics restored the attenuated LTP in aged rats. This
was accompanied by a modest decrease in markers of microglial acti-
vation and an increase in expression of BDNF and synapsin [15]. Bercik
et al. also reported that Biﬁdobacterium longum normalized behavior
and BDNF mRNA [40]. BDNF, in turn, enhances and maintains LTP
induction and, therefore, it plays an important role in cognitive func-
tion [41].
Taken together, evidence specify a link between β-amyloid plaques
and synaptic activity. Consistently, studies of Athari Nik Azm et al. [24]
and Kiousi et al. [25], showed that clearance of β-amyloid plaques or
prevention of their formation could be a mechanism by which probio-
tics may optimize synaptic transmission in the hippocampus.
It has been proposed that microglia play a key role in neurode-
generative disorders. Through pruning synapses and increasing pro-
inﬂammatory cytokines in models of AD, [42] they inhibit LTP [43].
Hence, another possibility is that, through attenuating oxidative stres-
sors and pro-inﬂammatory biomarkers released from activated micro-
glia, probiotics improve activity of neuronal circuits.
Short-chain fatty acids, also aﬀect brain function in level of neu-
ronal activity. In line, butyrate, via extracellular signal regulated kinase
(ERK)-dependent mechanism [44], is capable of facilitating LTP and the
formation of long-term memory in rats. Lattal et al. demonstrated that
sodium butyrate facilitates neuronal plasticity and memory formation
[45].
Therefore, based on the evidence provided from either the animals
deprived from natural gut ﬂora (germ free animals) or those supporting
with probiotics, it seems that one of the main mechanism by which the
beneﬁcial bacteria aﬀects the activity of neuronal circuits is brain
neurochemistry. In this way, bacteria inﬂuence product of neuromo-
dulators, neurotransmitters and metabolites and, hence, aﬀect the brain
function. Nevertheless, more studies are required to clarify direct eﬀect
of gut microbiota and probiotics on synaptic transmission.
4.3. The eﬀect of probiotics on the anti-oxidant/oxidant factors
The biochemical assessments in the present study showed that the β-
amyloid administration increased the oxidant factor and decreased the
anti-oxidant index. The bacteroitherapy reversed the values in support
of anti-oxidants over oxidants.
A key mechanism associated with AD is oxidative stress [46] which
can be modiﬁed by nutritional or anti-oxidant supplements [47]. It is
reported that β-amyloid accumulation in neuron’s mitochondria is
concerned with generation of free radicals and oxidative stresses in
early stage of AD [48]. Also, since β-amyloid proceeds lipid peroxida-
tion [49], it possibly promotes production of oxidant stressors like
MDA. Reports conﬁrm that, via reducing inﬂammation and increasing
anti-oxidant enzymes, probiotic bacteria are capable to inhibit oxida-
tive stress [50] and that this anti-oxidative stress role of probiotics is
exerted by aﬀecting the gut microbiota [51]. Useful eﬀect of probiotics
on balance of anti-oxidant/oxidant biomarkers has been shown in ex-
perimental and clinical investigations. For instance Singh et al. reported
that Lactobacillus acidophilus application in rats attenuates oxido-ni-
trosative stress and pro-inﬂammatory TNF-α levels [52]. Clinical as-
sessments also indicate that probiotic intake decreases plasma level of
MDA in the multiple sclerosis and AD patients [14,53]. Hence, the
positive eﬀect on balance of the anti-oxidants/oxidants might be an-
other mechanism by which the probiotics aﬀect the brain function.
It should be noted that despite quantifying an approximated number
of bacteria in feces samples of the experimental subjects, however, as a
limitation of our work, phenotype of gut bacteria was not qualiﬁed.
Another limitation could be using multispecies probiotics, where the
behavioral and electrophysiological improving eﬀects cannot be
contributed to a speciﬁc probiotic bacterium.
5. Conclusion
Through microbiota-gut-brain axis, the gut microbiota can mod-
ulate host brain function. Evidences demonstrate that the pathology of
AD may be associated with disturbance of gut microbiota, and mod-
ulation of gut microbiota with probiotics beneﬁcially aﬀect AD [54].
Consistently, our results designate that the probiotic treatment im-
proves spatial performance and favorably aﬀect balance anti-oxidant/
oxidant biomarkers in the β-amyloid administered animals. Im-
portantly, this study provides the ﬁrst report indicating that probiotics
restores attenuated LTP in an animal model of AD. These ﬁndings re-
quest future researches concerning how the bidirectional pathway es-
tablished by the gut-brain-microbiota underlies normal and tetanized
synaptic transmission. Also, most of researches have considered multi
strain probiotic supplements, while evidence indicate that even strains
of the same species of probiotic bacteria diﬀerently aﬀect host phy-
siology [55]. Therefore, future research on probiotics must consider
strain as well as host, and sex speciﬁcity of their action and optimal
route for a maximum efﬁcacy [25].
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